A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval

Inclusion Criteria:

- Healthy male and female subjects, 18 to 65 years of age, inclusive. For Part B:
Healthy male and female subjects, 18 to 65 years of age, inclusive (female subjects
only if the repeat dose is tolerated in Part A)

- Healthy status is defined by absence of evidence of any clinically significant,
active or chronic disease following a detailed medical and surgical history, a
complete physical examination including vital signs, 12-lead ECG, hematology, blood
chemistry, serology and urinalysis

- A BMI between 18 to 32 kg/m2 inclusive

- Use of highly effective contraception

Exclusion Criteria:

- Pregnant or breast-feeding women

- Suspicion of alcohol or drug abuse or positive drug screen

- Positive result on hepatitis B (HBsAg), hepatitis C (HCV), or HIV 1 and 2

- History of any clinically significant gastrointestinal, renal, hepatic,
broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological,
hematological or allergic disease, metabolic disorder, cancer or cirrhosis

- Diseases or medical conditions that are capable of altering the absorption,
metabolism or elimination of drugs

- Any prescribed or over-the-counter medications (including vitamins or herbal
remedies) taken within 2 weeks prior to first dosing or within 5 times the
elimination half-life of the medication prior to first dosing (whichever is longer)

- Taking any nutrients known to modulate CYP3A activity (e.g., grapefruit juice;
Seville orange) within 2 weeks prior to administration of study drugs or tyramine
rich nutrients 48 hours prior to admission to study site and then throughout the
study

- Participation in an investigational drug or device study within 60 days prior to
screening or 5 times the elimination half-life of the medication prior to first
dosing (whichever is longer)

- Consumption of nicotine and/ or tobacco products within the last 45 days prior to Day
1 of study

Part B

- Any clinically significant cardiovascular findings or history of such

- Allergy to moxifloxacin or any quinolone antibiotics or history of tendon rupture
with quinolone-type antibiotic or any confirmed clinically significant allergic
reactions against any drug, or multiple allergies in the judgment of the Investigator